The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Avatrombopag vs. Placebo for CIT in GI Malignancies
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Avatrombopag for Persistent Chemotherapy-Induced Thrombocytopenia in Patients With Gastrointestinal Malignancies (ACT-GI)
Study ID: NCT05772546
Brief Summary: The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy. The names of the study drugs involved in this study are: * Avatrombopag (a thrombopoietin receptor agonist) * Matching placebo
Detailed Description: This is a randomized, double-blinded, placebo-controlled, multicenter phase 2 clinical trial evaluating Avatrombopag versus placebo for Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies. Avatrombopag may increase or stimulate megakaryocytes, which aid in producing blood platelets, resulting in an increased production of platelets. * Participants will be "randomized" into one of the study groups: Group A: Avatrombopag or Group B: Matching placebo. Randomization means that a participant is put into a group by chance. * All patients who complete the study (whether they received avatrombopag or placebo) have the opportunity to receive avatrombopag to treat CIT through a special free drug program available only to the participants of this study. The U.S. Food and Drug Administration (FDA) has not approved avatrombopag for CIT, but it has been approved for other uses. Study procedures include screening for eligibility, treatment visits, and blood tests. Participants will receive the study treatment or placebo for up to seven weeks and will be followed for up to 42 days after the last dose. It is expected that about 60 people will take part in this research study. Swedish Orphan Biovitrum (Sobi), biopharmaceutical company, is supporting this research study by providing the study drugs and funding.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Yale New Haven Hospital, New Haven, Connecticut, United States
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Cleveland Clinic, Cleveland, Ohio, United States
Oregon Health and Science University Hospital, Portland, Oregon, United States
University of Washington Fred Hutchinson Cancer Center, Seattle, Washington, United States
Name: Hanny Al-Samkari, MD
Affiliation: Massachusetts General Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Gerald A Soff, MD
Affiliation: University of Miami Cancer Center
Role: PRINCIPAL_INVESTIGATOR